Article

Suppression of miRs-497/195 axis possibly confers endocrine therapy resistance via elevated expression of FLT4 and the noncoding RNA MIR503HG

2024-05-17

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> Endocrine therapy resistance (ETR) in breast cancer is achieved via multiple pathways including a decrease in ER, dysregulation of cell cycle genes, and/or mutations in ER/co-activators/co-repressors. We have reported earlier that high expression of Jumonji domaining containing protein 6 (JMJD6) induced ETR by depleting ER expression. In this study, 3 cellular models represe...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 64d18ddb-3576-5f19-a804-6b827268b5f8
DOI: 10.1101/2024.05.14.594132

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Suppression of miRs-497/195 axis possibly confers endocrine therapy resistance via elevated expression of FLT4 and the noncoding RNA MIR503HGDOI 10.1101/2024.05.14.594132Read

Secondary Analysis of Human Bulk RNA-seq Dataset Suggest Potential Mechanisms and Transcriptional Biomarkers for Letrozole Resistance in Estrogen Positive (ER+) Breast CancerSemantic proximity Read

Loss function of tumor suppressor FRMD8 confers resistance to tamoxifen therapy via a dual mechanismSemantic proximity Read

EstroGene2.0: A multi-omic database of response to estrogens, ER-modulators, and resistance to endocrine therapies in breast cancerSemantic proximity Read

Differential gene expression in tamoxifen-resistant breast cancer cells revealed by a new analytical model of RNA-Seq data.Semantic proximity Read

PML1-Mediated Feedforward Loop Through PI3K and MAPK Axes Drives Endocrine ResistanceSemantic proximity Read

Long Non-Coding RNAs as New Master Regulators of Resistance to Systemic Treatments in Breast CancerSemantic proximity Read

Kinome Reprogramming Is a Targetable Vulnerability in ESR1 Fusion-Driven Breast Cancer.Semantic proximity Read

Estrogen regulation and functional role of FGFR4 in estrogen receptor positive breast cancerSemantic proximity Read

RRM2 as a Key Biomarker and Therapeutic Target in Letrozole-Resistant ER+ Breast Cancer: Insights from Bioinformatics and Molecular DockingSemantic proximity Read

Gene expression associated with endocrine therapy resistance in estrogen receptor-positive breast cancerSemantic proximity Read

Kinase Plasticity with Vandetanib Treatment Enhances Sensitivity to Tamoxifen in Estrogen Receptor Positive Breast CancerSemantic proximity Read

Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast CancerSemantic proximity Read